IBEX (NASDAQ:IBEX) Insider Christina Al Trofimuk-O’connor Sells 1,000 Shares of Company Stock

IBEX Limited (NASDAQ:IBEX) insider Christina O’Connor sold 1,000 shares of the stock in a transaction dated Tuesday, November 10th. The stock was sold at an average price of $51.46, for a total transaction of $51,460.00. Following the sale, the insider owned 37,424 shares in the company, valued at approximately $1,925,839.04. This trade represents a 2.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Christina Al Trofimuk-O’connor also recently made the following trade(s):

• On Wednesday, September 16th, Christina O’Connor sold 2,376 shares of IBEX stock. The stock was sold at an average price of $39.34, for a total transaction of $93,471.84.
• On Tuesday, September 15th, Christina O’Connor sold 7,500 shares of IBEX stock. The shares were sold at an average price of $40.30, for a total value of $302,250.00.

IBEX Trading Up 3.9%

Shares of IBEX stock opened at $52.23 on Wednesday. The business’s 50 day simple moving average is $43.52 and its 200-day simple moving average is $34.63. The stock has a market capitalization of $696.23 million, a price-to-earnings ratio of 15.83 and a beta of 0.74. IBEX Limited has a twelve month low of $25.94 and a twelve month high of $52.29.

IBEX (NASDAQ:IBEX) last released its quarterly earnings data on Thursday, November 5th. The company reported $1.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.90 by $0.20. IBEX had a return on equity of 29.10% and a net margin of 7.34%. The business had revenue of $175.23 million during the quarter, compared to analyst estimates of $169.31 million.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Weiss Ratings raised shares of IBEX from a “buy (b-)” rating to a “buy (b)” rating in a research note on Monday, October 12th. Wall Street Zen upgraded IBEX from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Royal Bank Of Canada lifted their target price on IBEX from $40.00 to $45.00 and gave the company a “sector perform” rating in a research note on Tuesday. Finally, Robert W. Baird boosted their price target on IBEX from $40.00 to $44.00 and gave the stock a “neutral” rating in a research report on Monday, September 28th. One equities research analyst has rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, IBEX currently has an average rating of “Hold” and an average price target of $44.50.

Institutional Trading of IBEX

A number of hedge funds and other institutional investors have recently made changes to their positions in IBEX. Ieq Capital LLC raised its holdings in IBEX by 11.8% during the third quarter. Ieq Capital LLC now owns 14,638 shares of the company’s stock worth $633,000 after purchasing an additional 1,545 shares in the last quarter. Boston Partners increased its position in shares of IBEX by 15.3% during the 3rd quarter. Boston Partners now owns 397,353 shares of the company’s stock valued at $17,189,000 after purchasing an additional 52,638 shares during the period. Virtus Advisers LLC raised its stake in shares of IBEX by 18.9% in the 3rd quarter. Virtus Advisers LLC now owns 22,920 shares of the company’s stock worth $992,000 after buying an additional 3,645 shares in the last quarter. Russell Investments Group Ltd. raised its stake in shares of IBEX by 370.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 14,361 shares of the company’s stock worth $623,000 after buying an additional 11,309 shares in the last quarter. Finally, Ritholtz Wealth Management boosted its stake in IBEX by 10.0% during the third quarter. Ritholtz Wealth Management now owns 60,230 shares of the company’s stock valued at $2,606,000 after buying an additional 5,480 shares in the last quarter. 81.24% of the stock is currently owned by institutional investors.

IBEX News Summary

Here are the key news stories impacting IBEX this week:

• Positive Sentiment: IBEX CEO Bob Dechant and CFO Taylor Greenwald are scheduled to present at the RBC 2026 Global TIMT Conference on November 17. The event offers an opportunity to discuss the business and its outlook, though no new financial guidance was announced. Conference announcement
• Neutral Sentiment: A short-interest report lists zero shares sold short as of November 10, despite characterizing short interest as having increased. If the zero figure is accurate, it indicates little reported short positioning; the conflicting description makes the update difficult to interpret.
• Negative Sentiment: RBC raised its price target to $45 from $40 but maintained a “sector perform” rating. The new target is below the recent share price, implying potential downside and suggesting the analyst sees limited near-term upside at current levels.
• Negative Sentiment: Six IBEX insiders, including CEO Dechant, reported share sales totaling about 31,200 shares. Dechant’s 5,000-share transaction was made under a pre-arranged Rule 10b5-1 plan, and sellers retained shares after their trades; nonetheless, the cluster of sales could weigh on sentiment. CEO filing Insider filing Insider filing Insider filing Insider filing Director filing

IBEX Company Profile

IBEX Limited (NASDAQ: IBEX) is a business process outsourcing and customer experience technology company. It provides customer service, technical support, sales, back-office processing and other digital services for businesses across industries, including communications, healthcare, retail, logistics and financial services. The company combines customer contact centers, digital engagement channels, analytics and artificial intelligence-enabled tools to help clients manage customer interactions and improve operational efficiency.